Del. Judge Finds Teva Infringed ADHD Drug IP On Remand

Law360 (December 1, 2020, 11:01 PM EST) -- A Teva unit infringed five valid Tris Pharma Inc. patents when applying to sell a generic version of the ADHD treatment Quillivant XR, a Delaware federal judge has ruled in an about-face from the court's first decision in the litigation. 

U.S. District Judge Colm F. Connolly ruled squarely in favor of Tris on Monday, saying Actavis Laboratories FL Inc. directly and contributorily infringed the patents and induced others to infringe them. Unlike the judge he'd inherited the case from, Judge Connolly said the patents weren't invalid as obvious.

Now-retired U.S. District Judge Gregory Sleet had found the patents invalid in 2017...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!